4.65 USD
+0.03 (+0.65%)
Taking everything into account, SRTA scores 3 out of 10 in our fundamental rating. SRTA was compared to 0 industry peers in the Unkown industry. The financial health of SRTA is average, but there are quite some concerns on its profitability. SRTA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SRTA has reported negative net income.
In the past year SRTA has reported a negative cash flow from operations.
SRTA had negative earnings in each of the past 5 years.
In the past 5 years SRTA always reported negative operating cash flow.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.05% | ||
| ROE | 14.27% | ||
| ROIC | N/A |
ROA(3y)-12.68%
ROA(5y)-33.09%
ROE(3y)-15.39%
ROE(5y)-48.99%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Gross Margin of SRTA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 17.65% | ||
| GM | 23.78% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.59%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for SRTA has been increased compared to 1 year ago.
SRTA has more shares outstanding than it did 5 years ago.
SRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.31 indicates that SRTA is not in any danger for bankruptcy at the moment.
SRTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.31 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
SRTA has a Current Ratio of 4.39. This indicates that SRTA is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 4.39 indicates that SRTA has no problem at all paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.39 | ||
| Quick Ratio | 4.39 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 60.87% over the past year.
SRTA shows a decrease in Revenue. In the last year, the revenue decreased by -5.40%.
Measured over the past years, SRTA shows a very strong growth in Revenue. The Revenue has been growing by 70.13% on average per year.
EPS 1Y (TTM)60.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y70.13%
Revenue growth 5YN/A
Sales Q2Q%-34.16%
3.2 Future
SRTA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.23% yearly.
The Revenue is expected to grow by 7.57% on average over the next years.
EPS Next Y75.19%
EPS Next 2Y49.01%
EPS Next 3Y24.23%
EPS Next 5YN/A
Revenue Next Year-23.72%
Revenue Next 2Y3.06%
Revenue Next 3Y7.57%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SRTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 56.99, SRTA can be considered very expensive at the moment.
When comparing the Price/Forward Earnings ratio of SRTA to the average of the S&P500 Index (23.80), we can say SRTA is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 56.99 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
SRTA's earnings are expected to grow with 24.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.01%
EPS Next 3Y24.23%
5. Dividend
5.1 Amount
No dividends for SRTA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SRTA (12/11/2025, 2:33:30 PM)
4.65
+0.03 (+0.65%)
Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change4.49%
Market Cap0
Revenue(TTM)228.76M
Net Income(TTM)40.39M
Analysts85
Price Target9.82 (111.18%)
Short Float %N/A
Short Ratio4.81
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-53.74%
Min EPS beat(2)-96.08%
Max EPS beat(2)-11.41%
EPS beat(4)1
Avg EPS beat(4)-16.86%
Min EPS beat(4)-96.08%
Max EPS beat(4)64.99%
EPS beat(8)3
Avg EPS beat(8)-46.19%
EPS beat(12)5
Avg EPS beat(12)-23.19%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)9.08%
Min Revenue beat(2)8.32%
Max Revenue beat(2)9.84%
Revenue beat(4)4
Avg Revenue beat(4)7.53%
Min Revenue beat(4)4.23%
Max Revenue beat(4)9.84%
Revenue beat(8)6
Avg Revenue beat(8)4.07%
Revenue beat(12)10
Avg Revenue beat(12)5.21%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)22.87%
PT rev (3m)N/A
EPS NQ rev (1m)-700%
EPS NQ rev (3m)N/A
EPS NY rev (1m)18.18%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)4.66%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-10.81%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 56.99 | ||
| P/S | 1.58 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.27 | ||
| P/tB | 2.42 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.27
EYN/A
EPS(NY)0.08
Fwd EY1.75%
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS2.95
BVpS3.65
TBVpS1.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.05% | ||
| ROE | 14.27% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 17.65% | ||
| GM | 23.78% | ||
| FCFM | N/A |
ROA(3y)-12.68%
ROA(5y)-33.09%
ROE(3y)-15.39%
ROE(5y)-48.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.59%
GM growth 5YN/A
F-Score3
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 209.44% | ||
| Cap/Sales | 6.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.39 | ||
| Quick Ratio | 4.39 | ||
| Altman-Z | 4.31 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)198.6%
Cap/Depr(5y)143.5%
Cap/Sales(3y)4.9%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
EPS Next Y75.19%
EPS Next 2Y49.01%
EPS Next 3Y24.23%
EPS Next 5YN/A
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y70.13%
Revenue growth 5YN/A
Sales Q2Q%-34.16%
Revenue Next Year-23.72%
Revenue Next 2Y3.06%
Revenue Next 3Y7.57%
Revenue Next 5YN/A
EBIT growth 1Y56.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year137.67%
EBIT Next 3Y40.45%
EBIT Next 5YN/A
FCF growth 1Y-64.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.84%
OCF growth 3YN/A
OCF growth 5YN/A
STRATA CRITICAL MEDICAL INC / SRTA FAQ
What is the ChartMill fundamental rating of STRATA CRITICAL MEDICAL INC (SRTA) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SRTA.
What is the valuation status for SRTA stock?
ChartMill assigns a valuation rating of 2 / 10 to STRATA CRITICAL MEDICAL INC (SRTA). This can be considered as Overvalued.
What is the profitability of SRTA stock?
STRATA CRITICAL MEDICAL INC (SRTA) has a profitability rating of 1 / 10.
How financially healthy is STRATA CRITICAL MEDICAL INC?
The financial health rating of STRATA CRITICAL MEDICAL INC (SRTA) is 6 / 10.